ESPharma
ActiveSummary
ESPharma has been active since 2024 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €55,529 and a net result of €40,204. Its solvency ranks better than 83% of 22,153 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.7% (low).
Directors
Directors
No sitting directors in the Gazette act read. See the directors and other office holders in the KBO →
Owners and capital
Owners
No owners or capital events in the accounts and acts we read.